Study of Zasocitinib for Active Crohn's Disease
Treatments studied
Part of Digestive system clinical trials.
This trial tests a new oral medicine called Zasocitinib for people with active Crohn's disease who have tried other treatments that no longer work or are not tolerated. The goal is to see if it can reduce inflammation and improve symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have been diagnosed with Crohn's disease for at least 30 days.
- You have tried other Crohn's treatments that either no longer help or cause side effects you cannot manage.
- You do not have another condition causing bowel inflammation.
- You do not have any active abscesses or had one treated in the last 6 weeks.
- You have not had bowel surgery in the last 6 months or other belly surgery in the last 3 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is for people who already completed 52 weeks of treatment with TAK-279 for ulcerative colitis or Crohn's disease and saw improvement. It gives them the option to continue the medication long-term to see if the benefits last.
This study tests a new targeted therapy for adults with moderate to severe Crohn's disease who haven't responded well to other treatments. It aims to reduce inflammation and improve symptoms.
This study tests two oral/ injectable medicines (upadacitinib and risankizumab) in adults with moderate-to-severe Crohn's who have already tried a TNF-blocker. It aims to see how well these treatments work in everyday practice.
This trial tests an experimental drug for people with moderate to severe Crohn's disease who haven't responded well to other treatments. The drug aims to reduce inflammation and may help improve symptoms.
This study tests advanced treatments for people with moderate to severe Crohn's disease or ulcerative colitis who haven't responded to at least one previous therapy. It aims to find better options for managing these conditions.
This study tests an experimental oral pill (SAR441566) for people with moderate to severe Crohn's disease. It aims to see if the drug can reduce inflammation and improve symptoms, especially for those who have not had success with other treatments.
Hear when a new Crohn’s disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.